Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group
1996

Paclitaxel for Malignant Pleural Mesothelioma

Sample size: 25 publication Evidence: low

Author Information

Author(s): J van Meerbeeck, C Debruyne, N van Zandwijk, PE Postmus, MC Pennucci, F van Breukelen, D Galdermans, H Groen, P Pinson, M van Glabbeke, E van Marck, G Giaccone

Primary Institution: University of Antwerp

Hypothesis

Does paclitaxel have any significant activity in treating chemotherapy-naive patients with malignant pleural mesothelioma?

Conclusion

Paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.

Supporting Evidence

  • No major objective responses were observed in the study.
  • Ten patients had stable disease, while the remaining showed disease progression.
  • The median survival time was 39 weeks, with a 1-year survival rate of 30%.

Takeaway

Doctors tested a medicine called paclitaxel on patients with a serious lung disease, but it didn't help them get better.

Methodology

The study involved 25 chemotherapy-naive patients receiving paclitaxel intravenously every 3 weeks, with assessments of tumor response and toxicity.

Limitations

The study had a small sample size and no major objective responses were observed.

Participant Demographics

Patients were aged 18 to 75 years, with a performance status of 0 to 2.

Statistical Information

Confidence Interval

0% - 15%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication